Politics of the European Union too often have damaging consequences for developing countries. Fair Politics EU wants to give developing countries a fair chance at development. - Fair Politics NOW!
‘EU trade policies should support access to medicines and poverty reduction,’ say MEPs
Member of European Parliament (MEP) Pedro Silva Pereira (S&D) has raised the idea of creating a special fund for developing countries to help them adjust to trade agreements with the EU. Furthermore, trade agreements should contribute to the development of public healthcare and access to medicines, according to several MEPs. The much-debated TTIP agreement should also have positive effects in developing countries. - 28-06-2016
Access to medicines for all
In her written questions Basterrechea (ALDE) refers to Article 208 of the Lisbon Treaty which outlines the principle of Policy Coherence for Development (PCD). It requires that European Union (EU) should take into account the interest of developing countries and protect their well-being in policy-making. - 15-02-2016
MEP Rossi asks questions about the EU-India FTA and access to care
MEP Oreste Rossi (EPP) posed important questions towards the European Commission about the Free Trade Agreement (FTA) between EU and India. The questions concerned the effects of the FTA on access to care in least developed countries (LDCs). - 25-09-2013
MEP Tarabella asks questions about EU-India Free Trade Agreement
The importance of generic medicinal products for development countries is recognized by MEP Marc Tarabella (S&D). He proposed two questions to the Commission, where he discusses the agreement being negotiated between the EU and India, in which patents and data exclusivity rights will be expanded. This can have great negative consequences for the distribution of generic medicinal products, fighting diseases in developing countries. - 24-09-2013
TRIPS case update!
Our current case about TRIPS and access to medicines focuses on the Andean Example. Since a couple of years, the EU is negotiating free trade agreements (FTAs) with India and Thailand, which both may threaten access to medicines for poor people. Therefore, we think it is time to update this case again and make the EU aware of their incoherent policies within these FTAs. - 06-03-2013
Tarabella: biopiracy [is] a major concern for developing countries!
According to MEP Marc Tarabella (S&D), the depletion of genetic diversity, which plays an integral role in the process of biodiversity erosion, is one of the major challenges facing humanity, and wants to know how the Commissions wants to implement the Nagoya Protocol. - 25-02-2013
MEP Flaíková Benová asks question on biopiracy
In her question MEP Monika Flaíková Beòová (S&D) explains what biological piracy is, the patenting of medicinal properties of certain plants by pharmaceutical companies with as results that indigenous populations are paradoxically unable to make use of the resources that they themselves discovered. - 05-02-2013
MEP Hall makes amendment to biopiracy report
MEP Hall (ALDE) reacts to the draft report on the development aspects of intellectual property rights drafted by Catherine Grèze. She notes the importance of capacity building and legal assistance to enable developing countries to cope with patent applications systems and to ensure benefit sharing issues. - 29-10-2012
MEP Scholz pays attention to biopircay in draft opinion
MEP Scholzs (GUE/NGL) draft opinion on the development aspects of intellectual property rights ask to prevent against the negative aspects of the current intellectual property rights scheme for developing countries. - 25-10-2012
MEP Newton Dunn writes report on Horizon 2020
The draft opinions of MEP Newton Dunn (ALDE) on Horizon 2020 - the Framework Programme for Research and Innovation are adopted by the Development committee of the European Parliament. In the first draft opinion Newton Dunn reacts to the proposal laying down the rules for participation and dissemination in Horizon 2020. The second draft opinion concerns the establishment of the Horizon 2020 programme. - 05-09-2012
MEP Bearder asks for extension of TRIPS waiver for LDCs
People in the Least Developed Countries (LDCs) have limited or no access to basic services. One of the reasons they do have to some extent access to generic medicines is beacause of the TRIPS waiver. The TRIPS (Trade Related Aspects of Intellectual Property) agreement is meant to protect intellectual property and encourage innovation. - 11-01-2012
Don't forget TRIPS on generic medicines when tackling counterfeit medicines.
The trade in counterfeit medicines is a criminal act as there is no control on what ingredients are actually in the medicines, either too few or too many, or even toxic substances. This fraudulent trade seriously harms the poorest members of society, mainly in ACP countries where markets are not well organised and regulatory legislation is still at a drafting stage. The EU has amended a resolution in order to combat the entry of falsified medicinal products into the European legal supply chain. This EU resolution together with the resolution adopted by a group of ACP states to combat trade in conterfeit medicines is very good. - 31-05-2011
New study ones again demonstrates the impact of TRIPs on access to medicine
A policy guide published by the WHO and the International Centre for Trade and Sustainable Development (ICTSD), which addresses the impact of TRIPS and discusses how to improve access to medicines for the most vulnerable citizens throughout the world. - 23-03-2011
MEP Childers asks Commission how to eradicate TB
World wide millions of people die from Tuberculosis (TB). In Europe TB is eradicated, unfortunately this disease remains wide spread in developing countries. TB, together with malaria and AIDS, is considered one of the three big killers, nevertheless it remains a neglected disease. MEP Childers (S&D) mentions that Catherine Ashton, vice president of the Commission plans to finance vaccination programmes in Africa and South-East Asia, and thus he asked the Commission how they are going to eradicate TB world wide. - 23-11-2010
Sign this petition now!
Millions of people rely on generic medicines to stay alive. These medicines, mostly produced in India, are a lot cheaper than patented medicines. The European Commission has undertaken action against the production, registration, transportation and exportation of generic medicines. Médecins Sans Frontières (MSF) started a petition against this, since 80% of the HIV/AIDS medicines they use for treatments are generic. - 12-10-2010
MEP Pat the Cope Gallagher asks question about EU patent and its effects on development
Intellectual Property Rights are considered to be beneficial for producers, but when it comes to development, they often have a negative impact. One of the best examples is the availability of medicines in developing countries. For most diseases the cure is out there, but the patient simply cannot afford them, due to the patents on these medicines. There is little coherence in policies when the EUs development policy prioritises access to affordable medicines for developing countries, while at the same time, the EUs industrial and trade policy delays or complicates the access to developing countries markets of affordable medicines. - 21-09-2010
MEPs bring IPR to the Attention of the Commission this Spring
Thijs Berman (S&D), Maria Eleni Koppa (S&D), Ilda Figueiredo (GUE/NGL) and Joao Ferreira (GUE/NGL) all separately asked parliamentary questions concerning Intellectual Property Rights (IPR) and access to affordable medicines. - 26-05-2010
MEP Martin asks about TRIPs at JPA
David Martin, from the Socialists & Democrats Group, asks the Commission to comment on the negotiations concerning TRIPs plus provisions within the bilateral trade agreements with ACP countries. He expresses his concerns for the access to medicines in developing countries. - 13-04-2010
ACP-EU JPA Question by MEP Martin on Access to Medicines
As one can read in the Fair Politics Case Study on TRIPS and Medicines, the access to medicines for developing countries is of often difficult. Although the medicines exist, patients in developing countries can commonly not afford them due to the patents on the drugs. The development efforts of the EU prioritize access to affordable medicines for developing countries, but trade, industry and enterprise policies delay and complicate the access because of beliefs in the innovative force of intellectual property rights. - 04-03-2010
Seizure of generic medicines: problem solved? Not by far!
Earlier this year, in March, we reported on this website about questions asked by MEPs David Martin (PSE) and Corien Wortmann-Kool (EPP-DE) regarding the seizure of generic medicines, produced in India and on their way to Brazil and Nigeria, in the Netherlands. Seizing or even delaying the transhipment of medicines like these are harmful for people in developing countries, as their access to essential generic and thus cheaper medicines is severely hampered. This is an update on the current situation regarding the seizing of medicines in Europe. Problem solved, as the Commission said? Probably not. - 04-02-2010
MEPs ask questions about seizures of generic medicines on their way to developing countries
Following a similar incident in December last year, recently there has been another seizure of generic medicines at the Dutch airport Schiphol. MEPs David Martin (PES) and Corien Wortmann-Kool (PPE#8209;DE) asked questions about this very delicate matter to the Council and the Commission. The consignment of medicines was produced in India and on its way to Nigeria. - 04-02-2010
Patent demands of EU also a farmers and Greens concern
MEP Carl Schlyter (Verts/ALE)to the Commission in which he explains the issues with patents on seeds and hybrid plants that can negatively affect biodiversity. They are also a direct concern to small farmers, such as in Latin America, that use and trade these (traditional) seeds and now face limited access in an increasingly monopolised seed market. - 25-11-2009
Coherence star for MEPs Helmuth Markov and Thijs Berman
For their contribution as chairpersons'Â to the Expert meeting on Intellectual Property Rights (IPRs) which are included in the EU - CAN Association Agreement, Helmuth Markov (GUE-NGL) and Thijs Berman (PSE) have earned a coherence star on this website. - 03-11-2009
Oxfam and HAI report critices EU for "trading away access to medicine"
On the 19th of October Oxfam International and Health Action International (HAI) have published a critical report on EU policies that undermine the the right to health in developing countries. The clear incoherence between the EU pursuing trade agendas in favor of its pharmaceutical industry on the one hand and the support to the DOHA declaration and other efforts of the EC in improving access to health care in developing countries on the other hand, is strongly emphasised. At the same time, the EU does not do enough to support the medical innovation needed. - 28-10-2009
MEP Asa Westlund (S&D) concerned about EU demands in IPR in different Latin American negotiations
MEP Asa Westlund (S&D) asked the Commission whether it was true that they are negotiating an extension of patent terms and protection of data for medicine, as well as removing the Doha exception, in the negotiations with Peru and Colombia, but also with Central America. - 27-10-2009
Is the battle in the EU-Andean process over?
Today is the start of what is likely to be the last negotiation round for a free trade agreement between the EU and the Andean countries of Peru and Colombia. What started off two years ago as a region-to-region partnership agreement including a political and a development cooperation pillar, has been reduced to a bilateral commercial agreement. - 22-09-2009
The EU and Intellectual Property Rights
06 November 2008 -
MEPs: We will do everything in our power to make sure IPR provisions do not hinder access to medicines in Andean countries!
On February 17th, the EU Coherence Programme and Health Action International (HAI) in cooperation with the GUE/NGL and PSE groups organised an expert meeting on those provisions in the EU CAN Association Agreements that intend to protect Intellectual Property Rights (IPRs). -
MEP Grèze writes report on biopiracy and intellectual property rights
Today the draft Report of MEP Catherine Grèze (Greens/EFA) on intellectual property rights and biopiracy is discussed in the Development Committee (DEVE). - 18-9-2012
The EU and Intellectual Property Rights
06 November 2008 -